Form 4: MAIA Director Boosts Stake with Recent Stock Purchases

MAIA Biotechnology Director Cristian Luput acquired additional common stock through two separate transactions in late November 2025.

Summary

• Cristian Luput, a Director of MAIA Biotechnology, Inc. (MAIA), reported two direct purchases of common stock.
• On November 26, 2025, Mr. Luput purchased 20,000 shares of common stock at a price of $1.0808 per share.
• Following this transaction, Mr. Luput beneficially owned 419,483 shares directly.
• On November 28, 2025, an additional 18,145 shares of common stock were acquired at a weighted average price of $1.1149 per share.
• The shares purchased on November 28, 2025, were acquired in multiple transactions at prices ranging from $1.1147 to $1.1192.
• After both transactions, Mr. Luput's direct beneficial ownership increased to 437,628 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 8

Explanation: The sentiment is positive due to a director increasing their stake in the company, which typically signals confidence in future performance. The use of a 10b5-1 plan also suggests a deliberate, long-term investment strategy.

Positives

• A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reaction to immediate market events.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or operational outlook. It solely reports insider trading activity.

Management Comments

• The direct purchase of shares by Director Cristian Luput can be interpreted as a strong vote of confidence in MAIA Biotechnology's strategic direction and intrinsic value.

Industry Context

Insider buying, particularly by a director, is often viewed by the market as a positive indicator, suggesting that those closest to the company believe its stock is undervalued or that significant positive developments are anticipated. In the biotechnology sector, such confidence from leadership can be particularly impactful given the long development cycles and inherent risks.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the director's increased stake as a positive signal, potentially boosting investor confidence and demand for the stock.
• Employees: Could interpret the insider buying as a sign of stability and positive future outlook for the company.

Key Dates

Recommendation

The direct purchase of a significant number of shares by a company director, especially under a Rule 10b5-1 plan, is a strong indicator of insider confidence. This action suggests that management believes the stock is currently undervalued or expects positive developments, making it a compelling 'buy' signal for investors.

Keywords

MAIA Biotechnology, MAIA, Cristian Luput, Insider Trading, Form 4, Stock Purchase, Director, Common Stock, Beneficial Ownership, Rule 10b5-1